Biological hazards? VelaLabs is prepared to support you

VelaLabs - A Tentamus Company

ID: 1550628
recent pressrelease next pressrelease

(PresseBox) - Originator companies and generic/biosimilar companies in the (bio)pharmaceutical industry are working more and more with different biological materials of animal or human origin. Cell lines from bacteria, plants, animal and/or humans as well as viruses are used in the development and manufacturing of modern (bio)pharmaceutical products. This brings also new hazards (biohazards) into the work-areas where these biological materials are handled.

For classical pharmaceutical products, good manufacturing practice (GMP) ensures that pharmaceutical products are manufactured consistently and in a controlled way according to appropriate quality standards. Regulatory agencies worldwide require to meet GMP guidelines from producers and sellers of pharmaceutical products.

But now, as described above, some specific products such as certain vaccines or products derived from genetically modified organisms (GMOs) require complete different guidelines. This fact is also valid for biologics, biopharmaceuticals, biosimilars and advanced therapy medicinal products (ATMPs). The respective guidelines are summarized under the term biosafety. Biosafety defines the conditions, techniques and equipment used to prevent personal, laboratory and environmental exposure to potentially infectious or harmful agents. Depending on the risk class of these agents, manipulations with them have to be carried out in BSL1 to BSL4 laboratories (demanding increasing safety measures).

In certain cases, it might come to clashes between GMP requirements and biosafety. GMP guidelines, which have the product safety in their focus, demand the ?keep out? principle to protect the product whereas biosafety often requires the ?keep in? principle to protect the employees and environment. Starting from BSL2, safety of employees and environment generally overrules product safety. In this case, a defined risk assessment is necessary in order to find an alternative way to fulfill all GMP requirements and have patients/operator safety in perspective.



VelaLabs, a member of Tentamus Pharma Group, is well experienced in the field of biosafety laws including handling and storage of GMOs. Thus, VelaLabs is one of the few laboratories worldwide, which can support your analytical testing requirements in a combination of GMP and BSL2 conditions.

Contact our experts for further information.

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrochemicals, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 52 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.



More information:
http://bit.ly/2G6Yjgf http://bit.ly/2G7M6aT http://bit.ly/2G9E7dv http://bit.ly/2G6YacH http://bit.ly/2G6Y9p9 http://bit.ly/2G87HQq http://bit.ly/2G4pyHZ http://bit.ly/2G7WJKR https://www.ceramic-polymer.de/index.php?id=38&tx_ttnews%5Btt_news%5D=656&cHash



Keywords (optional):



Company information / Profile:

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food&feed, pharmaceuticals&medical, agrochemicals, cosmetics, agriculture&environment and nutraceutical&supplements). Tentamus Group is represented in over 52 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

PressRelease by

Requests:



PressContact / Agency:



published by: PresseBox
print pressrelease  send to a friend  

Date: 07/11/2019 - 03:00
Language: English
News-ID 1550628
Character count: 3662
Kontakt-Informationen:
Firma: Tentamus Group GmbH
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Vienna
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 348

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 70


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.